Lin Li Zhou, Li Fan, Liu Yang, Xing Ling Xi, Du Lian Fang
Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of
Med Ultrason. 2016 Jun;18(2):163-9. doi: 10.11152/mu.2013.2066.182.ceu.
To evaluate the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) as a method for diagnosing pancreatic lesions with regard to the ductal pancreatic carcinoma and the differentiation of neoplastic from non-neoplastic lesions.
Relevant studies published by September 6, 2015 were retrieved from PubMed, Embase, and Cochrane Central Trials databases. The articles included were mainly based on the following criteria: use of CEUS as the diagnostic tool, and the use of histology as the reference method. Two independent reviewers inspected all these papers to confirm the matching of the inclusion criteria. One reviewer with methodological expertise extracted the data from the included studies. Sensitivity, specificity and diagnostic odds ratio (DOR) were used to obtain overall estimates.
Eighteen studies out of 734 articles initially identified met the inclusion criteria. The primary study objective with respect to ductal adenocarcinoma was verified in 15 studies. The pooled estimate of CEUS sensitivity for the differential diagnosis of duct adenocarcinomas was 0.90 (95 % CI, 0.89-0.92), and the specificity was 0.88 (0.84-0.90). The pooled estimate for DOR was 56.38 (29.91-106.33). The area under the curve under the summary receiver operating characteristic (SROC) was 0.95. 12 out of 18 studies examined CEUS sensitivity and the average specificity with regard to the secondary study objective, distinguishing between neoplastic lesions and non-neoplastic lesions, were 0.95 (0.94-0.96) and 0.83 (0.77-0.87). The pooled estimate for DOR was 73.25 (45.31-118.43). The area under the SROC curve was 0.96.
CEUS is a promising, reliable modality for the differential diagnosis of pancreatic adenocarcinoma in patients with pancreatic mass lesions. The presence of a hypoenhanced lesion was a sensitive predictor of pancreatic adenocarcinomas. It seems to be a useful tool in clinical practice.
评估超声造影(CEUS)作为诊断胰腺病变的方法在诊断导管腺癌以及区分肿瘤性与非肿瘤性病变方面的诊断准确性。
从PubMed、Embase和Cochrane Central Trials数据库中检索截至2015年9月6日发表的相关研究。纳入的文章主要基于以下标准:使用CEUS作为诊断工具,以及使用组织学作为参考方法。两名独立的审阅者检查所有这些论文以确认符合纳入标准。一名具有方法学专业知识的审阅者从纳入的研究中提取数据。使用敏感性、特异性和诊断比值比(DOR)来获得总体估计值。
最初确定的734篇文章中有18项研究符合纳入标准。15项研究验证了关于导管腺癌的主要研究目标。CEUS对导管腺癌鉴别诊断的敏感性合并估计值为0.90(95%CI,0.89 - 0.92),特异性为0.88(0.84 - 0.90)。DOR的合并估计值为56.38(29.91 - 106.33)。汇总受试者操作特征(SROC)曲线下面积为0.95。18项研究中有12项检查了CEUS对次要研究目标(区分肿瘤性病变和非肿瘤性病变)的敏感性,平均特异性分别为0.95(0.94 - 0.96)和0.83(0.77 - 0.87)。DOR的合并估计值为73.25(45.31 - 118.43)。SROC曲线下面积为0.96。
CEUS是一种有前景、可靠的方法,用于对胰腺肿块病变患者的胰腺腺癌进行鉴别诊断。低增强病变的存在是胰腺腺癌的敏感预测指标。它似乎是临床实践中的一种有用工具。